References
- Das, A., K. Saha, P.N. Ossorio. 2018. Fairness in manufacturing cellular therapies. American Journal of Bioethics 18 (4): 68–70.
- Frye, J. 2018. Perverse effects: How insufficient guidelines to IPFs undermine both research and health outcomes of clinical trials. American Journal of Bioethics 18 (4): 78–80.
- Gelinas, L., B.E. Bierer, I.G. Cohen. 2018. On scarcity and the value of clinical trials. American Journal of Bioethics 18 (4): 71–73.
- Jecker, N. S., A.G. Wightman, A. R. Rosenberg, and D.S. Diekema. 2017. From protection to entitlement: Ethical issues in selecting participants for clinical trials with breakthrough therapies. Journal of Medical Ethics 43 (6):391–400. doi:10.1136/medethics-2016-103868.
- Kang, J.S. 2018. Ethical ruminations of a rheumatologist: Autoimmunity is an important consideration for immunotherapy trials. American Journal of Bioethics 18 (4): 75–76.
- Milleson, V. 2018. Prioritizing facts and values in immunotherapy trial selection: Some further guidance. American Journal of Bioethics 18 (4): 76–78.
- Nakazawa, E., K. Yamamoto, and A. Akabayashi. 2018. Fairness and desert: A critique of the random selection criterion in clinical trials. American Journal of Bioethics 18 (4): 81–82.
- Pierson, L., J. Millum. 2018. Disease prevalence and the magnitude of research benefits. American Journal of Bioethics 18 (4): 73–74.